Spiramycin: the classic and the present | CMAC

Spiramycin: the classic and the present

Клиническая Микробиология и Антимикробная Химиотерапия. 2005; 7(3):301-312

​ Stratchounski L.S., Veselov A.V.
spiramycin macrolides review
Section
Antimicrobials
Type
Journal article
Publication
Клиническая Микробиология и Антимикробная Химиотерапия. 2005; 7(3):301-312

Abstract

Spiramycin is classic representative of the 16-membered macrolides, which was synthesized in 1954. Nevertheless he keeps his clinical significance due to the high activity against typical causative agents of respiratory tract, skin and soft tissues infections, activity against atypical pathogens, which causes infections of the respiratory and urinary tract, and also against protozoa (toxoplasma, cryptosporidium). High tissue concentrations, intracellular accumulation, low protein binding, lack of drug interactions permits benefit usage of spiramycin. The safety profile was confirmed in a great number of clinical trials, including pregnant. An existent experience of clinical usage of spiramycin in different countries, including Russia, allows to use it in a variety of indications in pulmonology, gynecology, obstetrics, pediatric, dermatology, venereology and stomatology.

  • 1. Finegold, S. M. In vitro efficacy of beta-lactam/ beta-lactamase inhibitor combinations against bacteria involved in mixed infections. Int.J.Antimicrob.Agents 1999;12 Suppl 1:S9-14.
  • 2. Kimura, K., Y. Arakawa, S. Ohsuka, H. Ito, K. Suzuki, H. Kurokawa, N. Kato, and M. Ohta. Molecular aspects of high-level resistance to sulbactam-cefoperazone in Klebsiella oxytoca clinical isolates. Antimicrob.Agents Chemother. 1996; 40:1988-1994.
  • 3. McLaughlin, J. C., A. L. Barry, P. C. Fuchs, E. H. Gerlach, D. J. Hardy, and M. A. Pfaller. In-vitro activity of five beta-lactam/beta-lactamase inhibitor combinations against consecutive isolates of the Enterobacteriaceae and Pseudomonas aeruginosa. J.Antimicrob.Chemother. 1994; 33:223-230.
  • 4. Nomura, S., H. Hanaki, and A. Nagayama. Tazo bactam-piperacillin compared with sulbac tam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections. J.Chemother. 1997; 9:89-94.
  • 5. Rice, L. B., L. L. Carias, L. Etter, and D. M. Shlaes. Resistan ce to cefoperazone-sulbactam in Klebsiella pneumoniae: evidence for enhanced resistance resulting from the coexistence of two different resistance mechanisms. Antimicrob.Agents Chemother. 1993; 37:1061-1064.
  • 6. Burgess, D. S. and R. G. Hall. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae. Diagn.Microbiol.Infect. Dis. 2004; 49:41-46.
  • 7. Kang, C.I., H. Pai, S.H. Kim, H.B. Kim, E.C. Kim, M.D. Oh, and K.W. Choe. Cefepime and the ino cu lum effect in tests with Klebsiella pneumoniae producing plasmid-mediated AmpC-type beta-lactamase. J.Antimicrob.Chemother. 2004; 54:1130-1133.
  • 8. Thomson, K. S. and E. S. Moland. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob.Agents Chemother. 2001; 45:3548-3554.
  • 9. Queenan, A. M., B. Foleno, C. Gownley, E. Wira, and K. Bush. Effects of inoculum and beta-lactamase activity in AmpC- and extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology. J.Clin.Microbiol. 2004; 42:269-275.
  • 10. Edelstein, M., Edelstein, I., Semchenkova, D., and Strat chounski, L. The effect of large inoculaon in vitro activities of penicillin-inhibitor combinations and cefoperazone-sulbactam against ESBL-producing Escherichia coli and Klebsiella pneumoniae strains. (14th European Congress of Clinical Microbiology and Infectious Diseases), P1723. 2004. Prague. 2004.
  • 11. Procop, G. W., M. J. Tuohy, D. A. Wilson, D. Williams, E. Hadziyannis, and G. S. Hall. Cross-class resistance to non-beta-lactam antimicrobials in extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Am.J.Clin.Pathol. 2003; 120:265-267.
  • 12. Spanu, T., F. Luzzaro, M. Perilli, G. Amicosante, A. Toniolo, and G. Fadda. Occurrence of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to beta-lactams and other antimicrobial drugs. Antimicrob.Agents Chemother. 2002; 46:196-202.
  • 13. Winokur, P. L., M. V. Eidelstain, O. Stetsiouk, L. Stratchounski, J. Blahova, G. K. Reshedko, M. A. et al. Russian Klebsiella pneumoniae isolates that express extended-spectrum beta-lactamases. Clin.Microbiol. Infect. 2000; 6:103-108.
  • 14. Paterson, D. L., L. Mulazimoglu, J. M. Casellas, W. C. Ko, H. Goossens, A. Von Gottberg, et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin. Infect.Dis. 2000; 30:473-478.
  • 15. Yu, W. L., R. N. Jones, R. J. Hollis, S. A. Messer, D. J. Biedenbach, L. M. Deshpande, and M. A. Pfaller. Molecular epidemiology of extended-spectrum beta-lac tamase-producing, fluoroquinolone-resistant isolates of Klebsiella pneumoniae in Taiwan. J.Clin.Microbiol. 2002; 40:4666-4669.
  • 16. Graffunder, E. M., K. E. Preston, A. M. Evans, and R. A. Venezia. Risk factors associated with extended-spectrum {beta}-lactamase-producing organisms at a tertiary care hospital. J.Antimicrob.Chemother. 2005.
  • 17. Sirot, D., C. De Champs, C. Chanal, R. Labia, A. Darfeuille-Michaud, R. Perroux, and J. Sirot. Translocation of antibiotic resistance determinants including an extended-spectrum beta-lactamase between conjugative plasmids of Klebsiella pneumoniae and Escherichia coli. Antimicrob.Agents Chemother. 1991; 35:1576-1581.
  • 18. Araque, M. and I. Rivera. Simultaneous presence of blaTEM and blaSHV genes on a large conjugative plasmid carried by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Am. J. Med. Sci. 2004; 327:118-122.
  • 19. Mammeri, H., L. M. Van De, L. Poirel, L. Martinez-Martinez, and P. Nordmann. Emergence of plasmid-mediated quinolone resistance in Escherichia coli in Europe. Antimicrob.Agents Chemother. 2005; 49:71-76.
  • 20. Wang, M., D. F. Sahm, G. A. Jacoby, and D. C. Hooper. Emerging plasmid-mediated quinolone resistance associated with the qnr gene in Klebsiella pneumoniae clinical isolates in the United States. Antimicrob.Agents Chemother. 2004; 48:1295-1299.
  • 21. Jones, R. N. and M. A. Pfaller. Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum beta-lactamase in Europe. Clin. Microbiol.Infect. 2003; 9:708-712.
  • 22. Bouchillon, S. K., B. M. Johnson, D. J. Hoban, J. L. Johnson, M. J. Dowzicky, D. H. Wu, et al. Determining incidence of extended spectrum beta-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001-2002. Int.J.Antimicrob.Agents 2004; 24:119-124.
  • 23. Nijssen, S., A. Florijn, M. J. Bonten, F. J. Schmitz, J. Verhoef, and A. C. Fluit. Beta-lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European Enterobacteriaceae isolates. Int. J.Antimicrob.Agents 2004; 24:585-591.
  • 24. Edelstein, M., M. Pimkin, I. Palagin, I. Edelstein, and L. Stratchounski. Prevalence and molecular epidemiology of CTX-M extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Russian hospitals. Antimicrob.Agents Chemother. 2003; 47:3724-3732.
  • 25. Методические указания МУК 4.2.1890-04. 2004. Определение чувствительности микроорганизмов к антибактериальным препаратам.
  • 26. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: 14th informational supplement. NCCLS document M100-S14. 2004. National Committee for Clinical Laboratory Standards, Wayne, PA.
  • 27. Mabilat, C. and S. Goussard. 1993. PCR detection and identification of genes for extended-spectrum b-lactamases, p. 553-562. In: D. H. Persing, T. F. Smith, F. C. Tenover, and T. J. White (eds.), Diagnostic molecular microbiology. Principles and Applications. American Society for Microbiology, Washington, DC.
  • 28. Edelstein, M., M. Pimkin, T. Dmitrachenko, V. Semenov, N. Kozlova, D. Gladin, et al.. Multiple outbreaks of nosocomial salmonellosis in Russia and Belarus caused by a single clone of Salmonella enterica serovar Typhimurium producing an extended-spectrum beta-lactamase. Antimicrob.Agents Chemother. 2004; 48:2808-2815.
  • 29. Ekimov, A., Edelstein, M., and Belousov, E. A single-tube PCR with MGB Eclipse probes for detection of SHV-type extended-spectrum beta-lactamases (ESBLs). (14th European Congress of Clinical Microbiology and Infectious Diseases), 2004; P944. Prague.
  • 30. Edelstein, M., Ekimov, A., and Stratchounski, L. Prevalence of mutations conferring extended-spectrum activity on SHV beta-lactamases produced by nosocomial isolates of Enterobacteriaceae from Russian nationwide sur vey. (44th Interscience Conference on Antimicrobial Agents and Chemotherapy), 2004; C2-13
  • 31. Washington, DC. 31. Livermore, D. M. beta-Lactamases in laboratory and clinical resistance. Clin.Microbiol.Rev. 1995; 8:557-584.
  • 32. Paterson, D. L. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin. Microbiol.Infect. 2000; 6:460-463.
  • 33. Paterson, D. L., W. C. Ko, A. Von Gottberg, J. M. Casellas, L. Mulazimoglu, K. P. Klugman, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J.Clin.Microbiol. 2001; 39:2206-2212.
  • 34. Paterson, D. L., W. C. Ko, A. Von Gottberg, S. Mohapatra, J. M. Casellas, H. Goossens, et al. 2004. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin. Infect.Dis. 39:31-37.
  • 35. Szabo, D., A. Mathe, Z. Filetoth, P. Anderlik, L. Rokusz, and F. Rozgonyi. In vitro and in vivo activities of amikacin, cefepime, amikacin plus cefepime, and imipenem against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain. Antimicrob.Agents Chemother. 2001; 45:1287-1291.
  • 36. Paterson, D. L., W. C. Ko, A. Von Gottberg, S. Mohapatra, J. M. Casellas, H. Goossens, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann.Intern.Med. 2004; 140:26-32.
  • 37. Ambrose, P. G., S. M. Bhavnani, and R. N. Jones. Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program. Antimicrob.Agents Chemother. 2003; 47:1643-1646.
  • 38. Maglio, D., C. Ong, M. A. Banevicius, Q. Geng, C. H. Nightingale, and D. P. Nicolau. Determination of the in vivo pharmacodynamic profile of cefepime against exten ded-spectrum-beta-lactamase-producing Escherichia coli at various inocula. Antimicrob.Agents Chemother. 2004; 48:1941-1947.
  • 39. Ромашов О. М., Яковлев С.В., Сидоренко С.В., и Бе ре зин А.Г. Эффективность цефепима при лечении нозокомиальных инфекций, вызванных энтеробактериями–продуцентами бета-лактамаз расширенного спектра. Инфекции и антимикробная терапия 2003; 5.
  • 40. Yakovlev, S., Romashov, O., Sidorenko, S. V., and Eryomina, L. Impact of extended-spectrum beta-lactamases produced by Gram-negative bacteria on efficacy of cephalosporins and quinolones. (15th European Congress of Clinical Microbiology and Infectious Diseases), 2005; P437. Copenhagen.
  • 41. Yu, W. L., M. A. Pfaller, P. L. Winokur, and R. N. Jones. Cefepime MIC as a predictor of the extended-spectrum beta-lactamase type in Klebsiella pneumoniae. Taiwan. Emerg.Infect.Dis. 2002; 8:522-524.
  • 42. Bonnet, R., J. L. Sampaio, R. Labia, C. De Champs, D. Sirot, C. Chanal, and J. Sirot. A novel CTX-M beta-lactamase (CTX-M-8) in cefotaxime-resistant Enterobacteriaceae isolated in Brazil. Antimicrob.Agents Chemother. 2000; 44:1936-1942.
  • 43. Bonnet, R. Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. Antimicrob. Agents Chemother. 2004; 48:1-14.
  • 44. Perilli M., D. Ettorre, B. Segatore, B. Caporale, F. De Santis, G. Pochetti, et al. Overexpression system and biochemical profile of CTX-M-3 extended-spectrum beta-lactamase expressed in Escherichia coli. FEMS Microbiol.Lett. 2004; 241:229-232.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared